MARK2 anticorps
MARK2
Reactivité: Humain, Souris, Rat
ELISA, IF, IHC (p)
Hôte: Lapin
Polyclonal
unconjugated
N° du produit ABIN5583192
-
-
Antigène
Voir toutes MARK2 Anticorps
-
MARK2
(MAP/microtubule Affinity-Regulating Kinase 2 (MARK2))
-
Reactivité
-
Humain, Souris, Rat
-
Hôte
-
Lapin
-
Clonalité
-
Polyclonal
-
Conjugué
-
Cet anticorp MARK2 est non-conjugé
-
Application
-
ELISA, Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
-
Fonction
-
Rabbit polyclonal antibody raised against synthetic peptide of MARK2.
-
Specificité
-
This antibody is specific to MARK2.
-
Réactivité croisée
-
Humain, Souris, Rat
-
Immunogène
-
A synthetic peptide corresponding to human MARK2.
-
Top Product
-
Discover our top product MARK2 Anticorps primaire
-
-
-
Indications d'application
-
Immunohistochemistry (1:50-1:100)
Immunofluorescence (1:500-1:1000)
ELISA (1:2000)
The optimal working dilution should be determined by the end user.
-
Restrictions
-
For Research Use only
-
-
Format
-
Liquid
-
Concentration
-
1 mg/mL
-
Buffer
-
In PBS, 150 mM NaCl, pH 7.4 (50 % glycerol, 0.02 % sodium azide)
-
Agent conservateur
-
Sodium azide
-
Précaution d'utilisation
-
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
-
-20 °C
-
Stockage commentaire
-
Store at -20°C.
Aliquot to avoid repeated freezing and thawing.
-
-
Antigène
-
MARK2
(MAP/microtubule Affinity-Regulating Kinase 2 (MARK2))
-
Autre désignation
-
MARK2 (MARK2 Produits)
-
Synonymes
-
anticorps EMK-1, anticorps EMK1, anticorps PAR-1, anticorps Par-1b, anticorps Par1b, anticorps AU024026, anticorps Emk, anticorps Par-1, anticorps mKIAA4207, anticorps microtubule affinity regulating kinase 2, anticorps MAP/microtubule affinity regulating kinase 2, anticorps MARK2, anticorps Mark2
-
Sujet
-
Full Gene Name: MAP/microtubule affinity-regulating kinase 2
Synonyms: EMK1,MGC99619,PAR-1,Par1b
-
ID gène
-
2011
-
Pathways
-
SARS-CoV-2 Protein Interactome, Phosphorylation & l'infection par le SRAS-CoV-2
-